Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) Operating Expenses (2016 - 2025)

Macrogenics (MGNX) has disclosed Operating Expenses for 14 consecutive years, with $53.3 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 26.13% to $53.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $222.3 million through Dec 2025, down 14.66% year-over-year, with the annual reading at $222.3 million for FY2025, 14.66% down from the prior year.
  • Operating Expenses for Q4 2025 was $53.3 million at Macrogenics, down from $54.2 million in the prior quarter.
  • The five-year high for Operating Expenses was $77.7 million in Q1 2022, with the low at $45.9 million in Q3 2023.
  • Average Operating Expenses over 5 years is $63.2 million, with a median of $62.9 million recorded in 2023.
  • The sharpest move saw Operating Expenses surged 31.94% in 2021, then plummeted 31.17% in 2023.
  • Over 5 years, Operating Expenses stood at $72.4 million in 2021, then dropped by 15.56% to $61.1 million in 2022, then decreased by 1.71% to $60.1 million in 2023, then increased by 20.17% to $72.2 million in 2024, then fell by 26.13% to $53.3 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $53.3 million, $54.2 million, and $59.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.